A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic HER2-Expressing Cancers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516010-38-00

Acronym

VIR-5818-V101

Enrollment

240

Registered

2024-08-27

Start date

2022-04-25

Completion date

Unknown

Last updated

2025-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with Locally Advanced or Metastatic HER2-Expressing Cancers

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Portugal, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026